Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm

What Was Tested

Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.

DPP4 also degrades the vasodilator brain natriuretic peptide (BNP) to a less potent metabolite.

This study tested the hypothesis that DPP4 inhibition potentiates the vasodilator responses to GLP-1 and BNP in the human forearm.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and crossover study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind BNP (Nesiritide) study, the assignments were hidden from both participants and investigators until the end.

In the crossover set-up each of the participants took both BNP (Nesiritide) and the comparison in turn, acting as their own control.

What Was Measured

This study tested the hypothesis that DPP4 inhibition potentiates the vasodilator responses to GLP-1 and BNP in the human forearm.

The subject headings attached to it are Dipeptidyl-Peptidase IV Inhibitors, Forearm, Glucagon-Like Peptide 1, Healthy Volunteers, Natriuretic Peptide, Brain, Pyrazines and Regional Blood Flow.

The authors tagged it with the keywords diabetes mellitus, dipeptidyl‐peptidase 4, glucagon‐like peptide‐1 and vasodilation.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of BNP (Nesiritide).

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Journal of the American Heart Association), a journal based in England.

More context: the BNP (Nesiritide) compound page, all human trials.